卵巢癌药物市场基于(关键地区、市场参与者、规模和份额)- 到 2030 年的预测

  • Report Code : TIPRE00003750
  • Category : Pharmaceuticals
  • Status : Data Released
  • No. of Pages : 150
Buy Now

【研究报告】卵巢癌药物市场规模预计将从2022年的21亿美元增长到2030年的38亿美元;预计 2022 年至 2030 年市场复合年增长率为 7.7%。

市场洞察和分析师观点:

卵巢癌发病率上升推动卵巢癌药物市场增长。然而,由于不良反应而导致的产品召回阻碍了市场增长。

增长动力:

卵巢癌发病率上升推动了对治疗选择的需求

卵巢癌是第七大癌症女性常见癌症,是继宫颈癌和子宫内膜癌之后的第三大常见妇科恶性肿瘤。根据世界卵巢癌联盟的报告,每年有 324,000 名女性被诊断患有卵巢癌,207,000 名女性死于该病。此外,大多数卵巢癌患者被诊断为晚期(局部晚期或转移性)疾病,因为没有可用于早期检测卵巢癌的公共卫生筛查计划。因此,卵巢癌发病率的上升推动了对有效治疗方案的需求。减瘤手术和铂类化疗相结合的一线治疗是新诊断患有晚期卵巢癌的女性的标准治疗方法。此外,批准的 PARP 抑制剂、olaparib、rucaparib 和 niraparib 等治疗选择是新诊断卵巢癌治疗的突破性选择。使用 PARP 抑制剂治疗晚期卵巢癌也已成为改善临床结果的有效治疗选择。这些抑制剂可在对第一次、第二次和第三次铂类化疗完全缓解 (CR) 后的新诊断病例中提供长期疗效和无进展生存期 (PFS)。

战略见解< br>
报告细分和范围:

卵巢癌药物市场分析是通过考虑以下细分进行的:类型、药物类别和分销渠道。

细分分析:

按类型划分,市场分为上皮性卵巢癌、生殖细胞卵巢癌和间质瘤。 2022年,上皮性卵巢癌细分市场占据最大的卵巢癌药物市场份额;预计同一细分市场在预测期内的复合年增长率最高为 8.2%。根据英国癌症研究中心的报告,上皮性卵巢癌是最常见的卵巢癌类型。例如,100 个卵巢肿瘤中近 90 个(90%)是上皮性肿瘤。患有侵袭性晚期卵巢癌的患者市场上的治疗选择有限。 2022 年 11 月,美国食品和药物管理局 (FDA) 宣布批准 Elahere Nutrition, Inc. 生产的“mirvetuximab soravtansine-gynx”用于治疗患有上皮性卵巢癌的成年患者。该候选药物治疗上皮性卵巢癌的医生推荐剂量为 6 mg/kg,每三周静脉输注一次。 2024年1月,FDA宣布批准“RC88”的快速通道指定(FTD),这是一种间皮素靶向抗体药物偶联物(ADC),用于治疗复发性上皮性卵巢癌患者。因此,药物批准数量的增加正在推动上皮性卵巢癌领域的卵巢癌药物市场。

按类型划分的卵巢癌药物市场 – 2022 年和 2030 年

卵巢癌药物市场趋势

联合药物治疗

一些医学研究机构正在开发治疗卵巢癌的新型联合药物。 2023 年 9 月,皇家马斯登的研究人员宣布了一种新的药物联合疗法,该疗法对晚期卵巢癌患者有效。研究人员测试了联合药物疗法对低度浆液性卵巢癌(LGSOC)的效果,这是一种罕见的卵巢癌,对治疗的反应率较差。 RAMP-201临床试验通过将avutometinib药物与defactinib联合进行,以研究它们对LGSOC患者的协同治疗效果。中期临床试验结果显示,接受该药物组合治疗的患者中,45% 的肿瘤明显缩小。联合疗法如此令人满意的临床效果,与英国上市的靶向治疗药物曲美替尼(Trametinib)的疗效相比,其疗效几乎是其两倍,而曲美替尼的缓解率仅为 26%。 2024年1月,FDA宣布批准SH-105组合药物用于治疗乳腺癌和卵巢癌患者。因此,联合药物疗法正在成为可能推动未来几年卵巢癌药物市场增长的新趋势。

区域分析:

卵巢癌药物市场报告的范围包括北美、欧洲、亚太地区、南美洲和中美洲以及中东和非洲。 2022年,北美占据最大的卵巢癌药物市场份额。该地区的市场增长是由顶级公司推出的产品数量不断增加以及主要市场参与者的存在推动的。美国是北美市场的最大贡献者。女性卵巢癌发病率的上升迫使公司和监管机构分别在该地区开发和批准创新药物。此外,合同临床研究组织 (CRO) 数量的增加有利于北美卵巢癌药物市场的增长。

行业发展和未来机遇:

卵巢癌药物市场预测可以帮助这个市场的利益相关者规划他们的增长战略。下面列出了市场领先企业的一些战略发展:

2022 年 11 月,ImmunoGen 的 ELAHERE(mirvetuximab soravtansine-gynx)获得 FDA 批准,用于治疗对铂类耐药的成年患者耐药上皮性卵巢癌。 ELAHERE 专门批准用于 FRα 阳性铂耐药卵巢癌患者,由于治疗选择有限且现有疗法的临床结果不佳,这种疾病是一种具有挑战性的疾病。竞争格局和主要公司:

Elli Lilly、阿斯利康、GSK、Zielab、ImmunoGen (AbbVie)、GeneTech (Roche)、Vivesto、Allarity Therapeutics, Inc.、Aeterna Zentaris 和 Luye Pharma 是卵巢癌药物市场报告中介绍的知名公司之一。这些公司专注于开发新技术、升级现有产品并扩大其地域分布,以满足全球不断增长的消费者需求。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which region is expected to witness significant demand for ovarian cancer drugs market in the coming years?

Global ovarian cancer drugs market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa and South & Central America. North America held the largest market share of the ovarian cancer drugs market in 2022.

Which are the top companies that hold the market share in ovarian cancer drugs market?

Elli Lilly and GeneTech (Roche) are the top two companies that hold huge market shares in the ovarian cancer drugs market.

Who are the key players in the ovarian cancer drugs market?

The ovarian cancer drugs market majorly consists of the players such Elli Lilly, AstraZeneca, GSK, Zielab, ImmunoGen (AbbVie), GeneTech (Roche), Vivesto, Allarity Therapeutics, Inc., Aeterna Zentaris, and Luye Pharma, and amongst others.

Which drug class segment held the largest share in the ovarian cancer drugs market?

The PARP inhibitors segment dominated the global ovarian cancer drugs market and held the largest market share in 2022.

Which type segment leads the ovarian cancer drugs market?

The epithelial ovarian cancer segment held the largest share of the market in the global ovarian cancer drugs market and held the largest market share in 2022.

What is ovarian cancer drugs market?

Ovarian cancer is a growth of cells that is formed in the ovaries where the cells can multiply quickly and invade destroying the healthy body tissues. Therefore, rising prevalence of ovarian cancer among women enhances therapeutic option and drugs.

What is the market CAGR value of ovarian cancer drugs market during forecast period?

The CAGR value of the ovarian cancer drugs market during the forecasted period of 2022-2030 is 7.7%.

The List of Companies - Ovarian Cancer Drugs Market

  1. Elli Lilly
  2. AstraZeneca
  3. GSK
  4. Zielab
  5. ImmunoGen
  6. GeneTech (Roche)
  7. Vivesto
  8. Allarity Therapeutics, Inc.
  9. Aeterna Zentaris
  10. Luye Pharma

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports